Skip to main content
. 2014 Mar 6;36(1):51–59. doi: 10.1093/eurheartj/ehu095

Figure 4.

Figure 4

SRT3025 increases Ldlr expression in AML12 hepatocytes and decreases Pcsk9 in the supernatant. Western blots of Ldlr, Pcsk9, and β-actin in cultured AML12 cells (A) treated with SRT3025 at indicated concentrations for 24 h and (B) incubated with 10 μM SRT3025 for the times indicated. (C) Relative mRNA expression levels of Ldlr and Pcsk9 in AML12 cells after incubation with 10 μM SRT3025 for 24 h. (D) Pcsk9 protein levels in the supernatant of AML12 cells incubated with 10 μM SRT3025 for the times indicated. (E) Pcsk9 immunoprecipiated from AML12 cells incubated with vehicle (Veh, DMSO) or 10 μM SRT3025, and blotted for Ldlr and Pcsk9. Pcsk9, proprotein convertase subtilisin/kexin type 9.